Lessons for human inflammatory bowel disease from experimental models

Current Opinion in Gastroenterology

Volumn 15, Issue 4, 1999, Pages 285-290

  Bhan, Atul K ^a   Mizoguchi, Emiko ^a   Smith, R Neal ^a   Mizoguchi, Atsushi ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AUTOANTIBODY; CD4 ANTIGEN; CYTOKINE; INTERLEUKIN 10; TRANSFORMING GROWTH FACTOR BETA;

ANTIGEN PRESENTATION; APPENDIX; ARTICLE; B LYMPHOCYTE; CECUM; COLITIS; CYTOKINE RELEASE; ENTERITIS; EXPERIMENTAL MODEL; HELPER CELL; HEREDITY; IMMUNE RESPONSE; IMMUNOREGULATION; INTESTINE FLORA;

EID: 0032794854     PISSN: 02671379     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001574-199907000-00002     Document Type: Article

References (66)

1. 1 Elson CO, Sartor RB, Tennyson GS, Riddell RH: Experimental models of inflammatory bowel disease. Gastroenterology 1995, 109:1344-1367.
2. 2 Strober W, Fuss IJ, Ehrhardt RO, Neurath M, Boirivant M, Ludviksson BR: Mucosal immunoregulation and inflammatory bowel disease: new insights from murine models of inflammation. Scand J Immunol 1998, 48:453-458. This is an excellent review of experimental models and the mechanisms involved in the development of IBD. The review focuses on the role of TGF-β-mediated oral tolerance in intestinal inflammatory responses.
3. 3 Bhan AK, Mizoguchi E, Mizoguchi A: New models of chronic intestinal inflammation. Curr Opin Gastroenterol 1994, 10:633-638.
4. 4 Neurath MF, Fuss I, Pasparakis M, Alexopoulou L, Haralambous S, Meyer zum Buschenfelde KH, et al: Predominant pathogenic role of tumor necrosis factor in experimental colitis in mice. Eur J Immunol 1997, 27:1743-1750.
5. 5 Boirivant M, Fuss IJ, Chu A, Strober W: Oxazolone colitis: a murine model of T helper cell type 2 colitis treatable with antibodies to interleukin 4. J Exp Med 1998, 188:1929-1939. Colitis was induced in SJL/J mice by rectal administration of the haptenating agent, oxazolone. The colitis was limited to the distal half of the colon and was characterized by inflammation of the superficial layers of mucosa associated with ulceration. The lesional tissue contained increased amounts of TH2 cytokines IL-4 and IL-5. Anti-IL-4 but not anti-IL-12 antibody administration led to amelioration of the disease process. The TH2 cytokine response in this model is counterbalanced by a marked TGF-β response.
6. 6 Hollander GA, Simpson SJ, Mizoguchi E, Nichogiannopoulou A, She J, Gutierrez-Ramos JC, et al: Severe colitis in mice with aberrant thymic selection. Immunity 1995, 3:27-38.
7. 7 Powrie F: T cells in inflammatory bowel disease: protective and pathogenic roles. Immunity 1995, 3:171-174.
8. 8 Powrie F, Carlino J, Leach MW, et al: A critical role for transforming growth factor-β but not interleukin-4 in the suppression of T helper type 1-mediated colitis by CD45RB(low) CD4+ T cells. J Exp Med 1996, 183:2669-2674.
9. 9 Ludviksson BR, Gray B, Strober W, Ehrhardt RO: Dysregulated intrathymic development in the IL-2-deficient mouse leads to colitis-inducing thymocytes. J Immunol 1997, 158:104-111.
10. 10 Clegg CH, Ruffles JT, Haugen HS, Hoggatt IH, Aruffo A, Durham SK, et al: Thymus dysfunction and chronic inflammatory disease in gp39 transgenic mice. Int Immunol 1997, 9:1111-1122.
11. 11 Mizoguchi A, Mizoguchi E, Chiba C, Spiekermann GM, Tonegawa S, Nagler-Anderson C, Bhan AK: Cytokine imbalance and autoantibody production in T cell receptor-α mutant mice with inflammatory bowel disease. J Exp Med 1996, 183:847-856.
12. 12 Groux H, O'Garra A, Bigler M, Rouleau M, Antonenko S, de Vries JE, Roncarolo MG: A CD4+ T-cell subset inhibits antigen-specific T-cell responses and prevents colitis. Nature 1997, 389:737-742.
13. 13 Chen Y, Kuchroo VK, Inobe J, Hafler DA, Weiner HL: Regulatory T cell clones induced by oral tolerance: suppression of autoimmune encephalomyelitis. Science 1994, 265:1237-1240.
14. 14 Mizoguchi A, Mizoguchi E, Smith RN, Preffer FI, Bhan AK: Suppressive role of B cells in chronic colitis of T cell receptor alpha mutant mice. J Exp Med 1997, 186:1749-1756.
15. 15 Ehrhardt RO, Ludviksson B: Induction of colitis in IL2-deficient-mice: the role of thymic and peripheral dysregulation in the generation of autoreactive T cells. Res Immunol 1997, 148:582-588.
16. 16 Ehrhardt RO, Ludviksson BR, Gray B, Neurath M, Strober W: Induction and prevention of colonic inflammation in IL-2-deficient mice. J Immunol 1997, 158:566-573.
17. 17 Simpson SJ, De Jong YP, Shah SA, Comiskey M, Wang B, Spielman JA, et al: Consequences of Fas-ligand and perforin expression by colon T cells in a mouse model of inflammatory bowel disease. Gastroenterology 1998, 115:849-855.
18. 18 Simpson SJ, Shah S, Comiskey M, de Jong YP, Wang B, Mizoguchi E, et al: T cell-mediated pathology in two models of experimental colitis depends predominantly on the interleukin 12/Signal transducer and activator of transcription (Stat)-4 pathway, but is not conditional on interferon gamma expression by T cells. J Exp Med 1998, 187:1225-1234.
19. 19 Berg DJ, Davidson N, Kuhn R, Muller W, Menon S, Holland G, et al: Enterocolitis and colon cancer in interleukin-10-deficient mice are associated with aberrant cytokine production and CD4+ TH1-like responses. J Clin Invest 1996, 98:1010-1020.
20. 20 Cong Y, Brandwein SL, McCabe RP, Lazenby A, Birkenmeier EH, Sundberg JP, Elson CO: CD4+ T cells reactive to enteric bacterial antigens in spontaneously colitic C3H/HeJBir mice: increased T helper cell type 1 response and ability to transfer disease. J Exp Med 1998, 187:855-864.
21. 21 Simpson SJ, Mizoguchi E, Allen D, Bhan AK, Terhorst C: Evidence that CD4+, but not CD8+ T cells are responsible for murine interleukin-2-deficient colitis. Eur J Immunol 1995, 25:2618-2625.
22. 22 Rincon M, Anguita J, Nakamura T, Fikrig E, Flavell RA: Interleukin (IL)-6 directs the differentiation of IL-4-producing CD4+ T cells. J Exp Med 1997, 185:461-469.
23. 23 Neurath MF, Fuss I, Schurmann G: Upregulation of the IL-12/STAT-4 signaling pathway distinguishes Crohn's disease from ulcerative colitis. Gastroenterology 1998, 114:G4299.
24. 24 Fuss U, Neurath M, Boirivant M, Klein JS, de la Motte C, Strong SA, et al: Disparate CD4+ lamina propria (LP) lymphokine secretion profiles in inflammatory bowel disease. Crohn's disease LP cells manifest increased secretion of IFN-gamma, whereas ulcerative colitis LP cells manifest increased secretion of IL-5. J Immunol 1996, 157:1261-1270.
25. 25 Parronchi P, Romagnani P, Annunziato F, Sampognaro S, Becchio A, Giannarini L, et al: Type 1 T-helper cell predominance and interleukin-12 expression in the gut of patients with Crohn's disease. Am J Pathol 1997, 150:823-832.
26. 26 Hornquist CE, Lu X, Rogers-Fani PM, Rudolph U, Shappell S, Birnbaumer L, Harriman GR: G(alpha)i2-deficient mice with colitis exhibit a local increase in memory CD4+ T cells and proinflammatory Th1-type cytokines. J Immunol 1997, 158:1068-1077.
27. 27 Davidson NJ, Hudak SA, Lesley RE, Menon S, Leach MW, Rennick DM: IL-12, but not IFN-gamma, plays a major role in sustaining the chronic phase of colitis in IL-10-deficient mice. J Immunol 1998, 161:3143-3149.
28. 28 Takeda K, Clausen BE, Kaisho T, Tsujimura T, Terada N, Forster I, Akira S: Enhanced Th1 activity and development of chronic enterocolitis in mice devoid of stat3 in macrophages and neutrophils. Immunity 1999, 10:39-49.
29. 29 Mizoguchi A, Mizoguchi E, Bhan AK: The critical role of interleukin-4 but not interferon-γ in the pathogenesis of colitis in T cell receptor α mutant mice. Gastroenterology 1999, 116:320-326.
30. 30 Neurath MF, Fuss I, Kelsall BL, Stuber E, Strober W: Antibodies to interleukin 12 abrogate established experimental colitis in mice. J Exp Med 1995, 182:1281-1290.
31. dim T cells. Gastroenterology 1998, 114:A904.
32. 32 Bertrand V, Quere S, Guimbaud R, Sogni P, Chauvelot-Moachon L, Tulliez M, et al: Effects of murine recombinant interleukin-10 on the inflammatory disease of rats transgenic for HLA-B27 and human beta 2-microglobulin. Eur Cytokine Netw 1998, 9:161-170.
33. 33 Mackay F, Browning JL, Lawton P, Shah S, Comiskey M, Bhan AK, et al: Both the lymphotoxin and tumor necrosis factor pathways are involved in experimental murine models of colitis. Gastroenterology 1998, 115:1464-1475.
34. -1- mice: an overview. J Leukoc Biol 1997, 61:389-396.
35. 35 Neurath MF, Fuss I, Kelsall BL, Presky DH, Waegell W, Strober W: Experimental granulomatous colitis in mice is abrogated by induction of TGF-beta-mediated oral tolerance. J Exp Med 1996, 183:2605-2616.
36. 36 Mizoguchi E, Mizoguchi A, Bhan AK: Role of cytokines in the early stages of chronic colitis in TCRα-mutant mice. Lab Invest 1997, 76:385-397.
37. 37 Guimbaud R, Bertrand V, Chauvelot-Moachon L, Quartier G, Vidon N, Giroud JP, et al: Network of inflammatory cytokines and correlation with disease activity in ulcerative colitis. Am J Gastroenterol 1998, 93:2397-2404.
38. 38 Watanabe M, Ueno Y, Yajima T, Okamoto S, Hayashi T, Yamazaki M, et al: Interleukin 7 transgenic mice develop chronic colitis with decreased interleukin 7 protein accumulation in the colonic mucosa. J Exp Med 1998, 187:389-402.
39. 39 Mombaerts P, Mizoguchi E, Grusby MJ, Glimcher LH, Bhan AK, Tonegawa S: Spontaneous development of inflammatory bowel disease in T cell receptor mutant mice. Cell 1993, 75:274-282.
40. 40 Strober W, Ehrhardt RO: Chronic intestinal inflammation: an unexpected outcome in cytokine or T cell receptor mutant mice. Cell 1993, 175:203-205.
41. 41 Ma A, Datta M, Margosian E, Chen J, Horak I: T cells, but not B cells, are required for bowel inflammation in interleukin 2-deficient mice. J Exp Med 1995, 182:1567-1572.
42. 42 Davidson NJ, Leach MW, Fort MM, Thompson-Snipes L, Kuhn R, Muller W, et al: T helper cell 1-type CD4+ T cells, but not B cells, mediate colitis in interleukin 10-deficient mice. J Exp Med 1996, 184:241-251.
43. 43 Mizoguchi E, Mizoguchi A, Chiba C, Niles JL, Bhan AK: Antineutrophil cytoplasmic antibodies in T-cell receptor alpha-deficient mice with chronic colitis. Gastroenterology 1997, 113:1828-1835.
44. 44 Seibold F, Brandwein S, Simpson S, Terhorst C, Elson CO: pANCA represents a cross-reactivity to enteric bacterial antigens. J Clin Immunol 1998, 18:153-160.
45. 45 Mizoguchi A, Mizoguchi E, Tonegawa S, Bhan AK: Alteration of a polyclonal to an oligoclonal immune response to cecal aerobic bacterial antigens in TCRα mutant mice with inflammatory bowel disease. Int Immunol 1996, 8:1387-1394.
46. 46 Kullberg MC, Ward JM, Gorelick PL, Caspar P, Hieny S, Cheever A, et al: Helicobacter hepaticus triggers colitis in specific-pathogen-free interleukin-10 (IL-10)-deficient mice through an IL-12-and gamma interferon-dependent mechanism. Infect Immun 1998, 66:5157-5166.
47. 47 Foltz CJ, Fox JG, Cahill R, Murphy JC, Yan L, Shames B, Schauer DB: Spontaneous inflammatory bowel disease in multiple mutant mouse lines: association with colonization by Helicobacter hepaticus. Helicobacter 1998, 3:69-78.
48. 48 Gaskins HR, Vondrak-Juergens GL, McCracken BA, Woolsey JH: Specific-pathogen-free conditions enhance inflammatory bowel disease in T-cell receptor knockout, but not C3H/HeJBir mice. Lab Anim Sci 1997, 47:650-655.
49. 49 Rath HC, Herfarth HH, Ikeda JS, Grenther WB, Hamm TE Jr, Balish E, et al: Normal luminal bacteria, especially Bacteroides species, mediate chronic colitis, gastritis, and arthritis in HLA-B27/human β2 microglobulin transgenic rats. J Clin Invest 1996, 98:945-953.
50. 50 Dianda L, Hanby AM, Wright NA, Sebesteny A, Hayday AC, Owen MJ: T cell receptor-α β-deficient mice fail to develop colitis in the absence of a microbial environment. Am J Pathol 1997, 150:91-97.
51. 51 Rath HC, Ikeda JS, Linde HJ, Scholmerich J, Wilson KH, Sartor RB: Varying cecal bacterial loads influence colitis and gastritis in HLA-B27 transgenic rats. Gastroenterology 1999, 116:310-319.
52. 52 Panwala CM, Jones JC, Viney JL: A novel model of inflammatory bowel disease: mice deficient for the multiple drug resistance, mdr1a, spontaneously develop colitis. J Immunol 1998, 161:5733-5744.
53. 53 Sellon RK, Tonkonogy S, Schultz M, Dieleman LA, Grenther W, Balish E, et al: Resident enteric bacteria are necessary for development of spontaneous colitis and immune system activation in interleukin-10-deficient mice. Infect Immun 1998, 66:5224-5231.
54. 54 Madsen KL, Tavernini MM, Doyle JSC, Fedorak RN: Lactobacillus species prevents development of enterocolitis in interleukin-10 gene deficient mice. Gastroenterology 1997, 112:A1030.
55. 55 Hermiston ML, Gordon JI: Inflammatory bowel disease and adenomas in mice expressing a dominant negative N-cadherin. Science 1995, 270:1203-1207.
56. 56 Baribault H, Penner J, Iozzo RV, Wilson-Heiner M: Colorectal hyperplasia and inflammation in keratin 8-deficient FVB/N mice. Genes Dev 1994, 8:2964-2973.
57. 57 Reinecker HC, MacDermott RP, Mirau S, Dignass A, Podolsky DK: Intestinal epithelial cells both express and respond to interleukin 15. Gastroenterology 1996, 111:1706-1713.
58. 58 Meijssen MA, Brandwein SL, Reinecker HC, Bhan AK, Podolsky DK: Alteration of gene expression by intestinal epithelial cells precedes colitis in interleukin-2-deficient mice. Am J Physiol (Gastrointest Liver Physiol 37) 1998, 274:G472-G479.
59. 59 Keates S, Keates AC, Mizoguchi E, Bhan AK, Kelly CP: Enterocytes are the primary source of the chemokine ENA-78 in normal colon and ulcerative colitis. Am J Physiol (Gastrointest Liver Physiol 36) 1997, 273:G75-G82.
60. 60 Mizoguchi A, Mizoguchi E, Chiba C, Bhan AK: Role of appendix in the development of inflammatory bowel disease in TCR-α mutant mice. J Exp Med 1996, 184:707-715.
61. 61 Rutgeerts P, D'Haens G, Hiele M, Geboes K, Vantrappen G: Appendectomy protects against ulcerative colitis. Gastroenterology 1994, 106:1251-1253.
62. 62 Russel MG, Dorant E, Brummer RJ, van de Kruijs MA, Muris JW, Bergers JM, et al: Appendectomy and the risk of developing ulcerative colitis or Crohn's disease: results of a large case-control study. South Limburg Inflammatory Bowel Disease Study Group. Gastroenterology 1997, 113:377-382.
63. 63 Duggan AE, Usmani I, Neal KR, Logan RFA: Appendectomy, childhood hygiene, Helicobacter pylori, and risk of inflammatory bowel disease: a case control study. Gut 1998, 43:494-498.
64. 64 Gusella JF, Podolsky DK: Inflammatory bowel disease: is it in the genes. Gastroenterology 1998, 115:1286-1289.
65. 65 Targan SR, Hanauer SB, van Deventer SJ, Mayer L, Present DH, Braakman T, et al: A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn's disease. Crohn's Disease cA2 Study Group. N Engl J Med 1997, 337:1029-1035.
66. 66 Hogaboam CM, Vallance BA, Kumar A, Addison CL, Grahamn FL, Gauldie J, Collins SM: Therapeutic effects of interleukin-4 gene transfer in experimental inflammatory bowel disease. J Clin Invest 1997, 100:2766-2776.